Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 45, Issue 9, Pages 3601-3606Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2010.05.005
Keywords
Palladium(II) complexes; Edda-type ligands; Antitumoral activity; Chronic lymphocytic leukemia cells
Categories
Funding
- Ministry of Science and Technological Development of the Republic of Serbia [142010, 142008, 145065]
- EC
Ask authors/readers for more resources
Four novel bidentate N,N'-ligand precursors, including O,O'-dialkyl esters (alkyl = ethyl, n-propyl, n-butyl and n-pentyl), L1 center dot 2HCl-L4 center dot 2HCl, of (S,S)-ethylenediamine-N,N'-di-2-(4-methyl)-pentanoic acid dihydrochloride [(S,S)-H(4)eddl]Cl-2 and the corresponding palladium(II) complexes 1-4, were prepared and characterized by IR, H-1 NMR and C-13 NMR spectroscopy and elemental analysis. In vitro cytotoxicity of all compounds was determined against chronic lymphocytic leukemia cells (CLL). The compounds were found to exhibit higher antitumoral activity than cisplatin. The most active compound 2, [PdCl2{(S,S)-nPr(2)eddl}], was found to be 13.6 times more active than cisplatin on CLL cells. (C) 2010 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available